IMMUNOMEDICS, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 32049
 
  
 
C07K PEPTIDES 19119
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 3465
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 25142
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 19187
 
  
 
A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY 18136
 
  
 
A61N ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 1889
 
  
 
B82Y SPECIFIC USES OR APPLICATIONS OF NANO-STRUCTURES; MEASUREMENT OR ANALYSIS OF NANO-STRUCTURES; MANUFACTURE  OR TREATMENT OF NANO-STRUCTURES1637
 
  
 
C07D HETEROCYCLIC COMPOUNDS 12150
 
  
 
A61B DIAGNOSIS; SURGERY; IDENTIFICATION 11229

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0334,996 FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASESAug 02, 17Nov 23, 17[A61K, C12N, C07K]
2017/0326,238 CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLSJul 19, 17Nov 16, 17[A61K, C07K]
2017/0281,791 ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOFMay 26, 17Oct 05, 17[A61K, C07K]
2017/0283,442 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other MoleculesJun 13, 17Oct 05, 17[C07F, C07D, C07B, C07K]
2017/0274,079 RS7 AntibodiesJun 05, 17Sep 28, 17[A61K, C07K]
2017/0274,093 COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCERJun 09, 17Sep 28, 17[A61K, C07K]
2017/0224,837 COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERSFeb 10, 17Aug 10, 17[A61K, C07K]
2017/0173,167 Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody FragmentsMar 01, 17Jun 22, 17[A61K]
2017/0165,370 ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKERFeb 24, 17Jun 15, 17[A61K, C07K, B01D]
2017/0151,356 Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell DiseasesFeb 14, 17Jun 01, 17[A61K, C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9920116 Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodiesSep 22, 17Mar 20, 18[A61K, C07K]
9855344 Antibody-SN-38 immunoconjugates with a CL2A linkerFeb 24, 17Jan 02, 18[A61K, C07K, B01D]
9849176 RS7 antibodiesJun 05, 17Dec 26, 17[A61K, C07K]
9833511 RS7 antibodiesApr 23, 14Dec 05, 17[A61K, C07K]
9809646 Methods for treating thrombosis using chimeric and humanized anti-histone antibodiesApr 14, 17Nov 07, 17[A61K, C07K]
9797907 Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cellsApr 22, 16Oct 24, 17[A61K, G01N]
9770517 Anti-Trop-2 antibody-drug conjugates and uses thereofJul 01, 14Sep 26, 17[A61K, C07K]
9757458 Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cellsSep 22, 15Sep 12, 17[A61K, C07K]
9751948 Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)Aug 01, 16Sep 05, 17[A61K, G01N, A61P, C07K]
9745374 Fusion proteins containing recombinant cytotoxic RNAsesFeb 22, 12Aug 29, 17[A61K, C12N, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0266,310 PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCERAbandonedMay 31, 17Sep 21, 17[A61K, C07K]
2017/0137,534 Anti-Pancreatic Cancer AntibodiesAbandonedFeb 01, 17May 18, 17[A61K, C07K]
2016/0347,857 ANTIBODIES REACTIVE WITH AN EPITOPE LOCATED IN THE N-TERMINAL REGION OF MUC5AC COMPRISING CYSTEINE-RICH SUBDOMAIN 2 (CYS2)AbandonedAug 12, 16Dec 01, 16[A61K, G01N, C07K]
2016/0279,239 SUBCUTANEOUS ADMINISTRATION OF ANTI-CD74 ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND AUTOIMMUNE DISEASEAbandonedApr 18, 16Sep 29, 16[A61K, C07K]
2016/0250,350 DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETINGAbandonedMay 11, 16Sep 01, 16[A61K, C07K]
2016/0199,524 RADIOSENSITIVITY OF FLUOROPHORES AND USE OF RADIOPROTECTIVE AGENTS FOR DUAL-MODALITY IMAGINGAbandonedDec 09, 15Jul 14, 16[A61K, C07K]
2016/0090,413 ANTI-MUCIN ANTIBODIES FOR EARLY DETECTION AND TREATMENT OF PANCREATIC CANCERAbandonedDec 08, 15Mar 31, 16[A61K, G01N, C07K]
2016/0045,626 Methods and Compositions for Improved Labeling of Targeting PeptidesAbandonedOct 26, 15Feb 18, 16[A61K]
2016/0039,941 IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLSAbandonedSep 21, 15Feb 11, 16[A61K, C07K]
2016/0024,212 Humanized Anti-HLA-DR AntibodiesAbandonedOct 08, 15Jan 28, 16[A61K, C07K]
2015/0320,872 Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic CancerAbandonedJun 19, 15Nov 12, 15[A61K, C07K]
2015/0306,244 Anthracycline-Antibody Conjugates for Cancer TherapyAbandonedJul 08, 15Oct 29, 15[A61K]
2015/0307,524 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other MoleculesAbandonedJun 30, 15Oct 29, 15[C07F, C07D, C07B]
2015/0252,110 Anti-CD19 AntibodiesAbandonedMay 08, 15Sep 10, 15[A61K, C07K]
2015/0224,192 Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody FragmentsAbandonedApr 24, 15Aug 13, 15[A61K]
2015/0217,006 AL-F-18-LABELED, AL-F-19-LABELED AND GA-68-LABELED GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-ANTAGONISTS FOR IMAGING OF PROSTATE CANCERAbandonedJan 19, 15Aug 06, 15[A61K]
2015/0202,319 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased ToxicityAbandonedApr 01, 15Jul 23, 15[A61K]
2015/0196,653 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased ToxicityAbandonedMar 30, 15Jul 16, 15[A61K, C07K]
2015/0196,665 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased ToxicityAbandonedMar 27, 15Jul 16, 15[A61K, C07K]
2015/0196,654 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased ToxicityAbandonedMar 31, 15Jul 16, 15[A61K, C07K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.